KZA 0.00% 8.0¢ kazia therapeutics limited

Paxalisib GBM AGILE study

  1. 1,137 Posts.
    lightbulb Created with Sketch. 816
    Since we are on the cusp of the most important stage of Paxalisib's validation process for trial registration. Posters link to GBM AGILE.

    "GBM AGILE is an entirely unique approach to clinical trials made possible by the partnership and collaboration of clinicians, researchers, governments, regulatory agencies, pharmaceutical companies, and patient advocacy groups."

    "This new clinical trial approach is advantageous to GBM patients because it will help to identify effective treatments faster, allowing researchers to simultaneously and dynamically study the effects of multiple unique drugs."

    https://www.gcaresearch.org/gbm-agile/

    Regards
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.